It is a regenerative medicine company.
BlueRock Therapeutics is a biotech company that plans to develop induced pluripotent stem cell (iPSC) therapies to cure a range of diseases using an industry-leading platform. One of the initial programs is to regenerate heart muscle in patients who have had a heart attack (myocard infarction, MI) or are suffering from chronic heart failure, leading causes of morbidity and mortality worldwid.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Dec 12, 2016 | Series A | $225M | 2 | Bayer Versant Ventures | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Bayer | Yes | Series A |
Versant Ventures | Yes | Series A |